Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study

Anna Bodzenta-Lukaszyk, Andrzej Dymek, Kirsten McAulay, Heikki Mansikka, Anna Bodzenta-Lukaszyk, Andrzej Dymek, Kirsten McAulay, Heikki Mansikka

Abstract

Background: The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/formoterol, flutiform ®) in a single aerosol inhaler. This 12-week, open-label, randomized, active-controlled, parallel-group, multicentre, phase 3 study compared the efficacy and safety of fluticasone/formoterol with the commercially available combination product fluticasone/salmeterol.

Methods: Patients aged ≥ 18 years (N = 202) with mild-to-moderate-severe, persistent asthma for ≥ 6 months prior to screening were included in the study. After a screening phase (4-10 days), eligible patients were randomized 1:1 to receive fluticasone/formoterol or fluticasone/salmeterol during the 12-week treatment period. The primary objective was to demonstrate non-inferiority of fluticasone/formoterol versus fluticasone/salmeterol, measured by pre-dose forced expiratory volume in the first second (FEV1), at week 12.

Results: Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean pre-dose FEV1 at week 12. The new combination was also comparable to fluticasone/salmeterol for change from baseline to week 12 in pre-dose FEV1, change from pre-dose FEV1 at baseline to 2-hour post-dose FEV1 at week 12 and discontinuations due to lack of efficacy. Importantly, fluticasone/formoterol was superior to fluticasone/salmeterol in time to onset of action throughout the duration of the study. The two treatments demonstrated similar results for various other secondary efficacy parameters, including other lung function tests, patient-reported outcomes, rescue medication use, asthma exacerbations and Asthma Quality of Life Questionnaire scores. Fluticasone/formoterol was well tolerated and had a good safety profile that was similar to fluticasone/salmeterol.

Conclusions: The results of this study indicate that fluticasone/formoterol is as effective as fluticasone/salmeterol, and has a more rapid onset of action, reflecting the faster bronchodilatory effects of formoterol compared with those of salmeterol. If patients perceive the benefits of therapy with fluticasone/formoterol more rapidly than with fluticasone/salmeterol, this could have a positive impact on preference and adherence.

Trial registration: ClinicalTrials.gov NCT00476073.

Figures

Figure 1
Figure 1
Participant flow.
Figure 2
Figure 2
Mean (± 95% CI) pre-dose FEV1 throughout treatment. Data shown for per protocol population. Least-squares mean of the treatment difference at week 12: –0.061 L; 95% CI: –0.161, 0.040; p = 0.007, demonstrating non-inferiority. CI, confidence interval; FEV1, forced expiratory volume in the first second.
Figure 3
Figure 3
Time to onset of action of study medication at baseline (day 0; similar plots were obtained at weeks 2, 6 and 12). Data based on Kaplan-Meier survival analysis (full analysis set). Onset of action was defined as the first time point post-dose at which FEV1 was at least 12% greater than the pre-dose value. Analysis of time to onset of action using the multiple failures time model showed superiority of fluticasone/formoterol over fluticasone/salmeterol (hazard ratio: 1.64; 95% CI: 1.28, 2.10; p < 0.001). On day 0, more than twice as many patients had a bronchodilatory response that met the onset of action criterion in the fluticasone/formoterol group than in the fluticasone/salmeterol group at 5 minutes post-dose (39% versus 14%, respectively). In addition, a larger proportion of patients in the fluticasone/formoterol group met the onset of action criteria within 2 hours (post-dose), than in the fluticasone/salmeterol group (77% versus 64%, respectively; day 0). This trend continued over the 12-week treatment period, with consistently more patients achieving the predefined onset of action response in the fluticasone/formoterol group than in the fluticasone/salmeterol group at each post-dose time point (5–120 minutes). CI, confidence interval; FEV1, forced expiratory volume in the first second.

References

    1. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma, a report for the Global Initiative for Asthma. 2004.
    1. Dean BB, Calimlim BM, Kindermann SL, Khandker RK, Tinkelman D. The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma. 2009;46:861–866. doi: 10.3109/02770900903184237.
    1. Bahadori K, Doyle-Waters M, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24. doi: 10.1186/1471-2466-9-24.
    1. Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev. 2010;19:150–157. doi: 10.1183/09059180.00002110.
    1. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, Accordini S, Almar E, Bugiani M, Carolei A. et al.Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol. 2007;120:1360–1367. doi: 10.1016/j.jaci.2007.09.019.
    1. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J. 1996;9:636–642. doi: 10.1183/09031936.96.09040636.
    1. Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, Pirina P, Carrozzi L, Dallari R, De Togni A, de Marco R. Poor control increases the economic cost of asthma. Int Arch Allergy Immunol. 2006;141:189–198. doi: 10.1159/000094898.
    1. Partidge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. doi: 10.1186/1471-2466-6-13.
    1. Braido F, Baiardini I, Stagi E, Piroddi MG, Balestracci S, Canonica GW. Unsatisfactory asthma control: astonishing evidence from general practitioners and respiratory medicine specialists. J Investig Allergol Clin Immunol. 2010;20:9–12.
    1. Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving. J Asthma. 2008;45:723–729. doi: 10.1080/02770900802395512.
    1. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29:587–595. doi: 10.1183/09031936.00080306.
    1. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245–51. doi: 10.1016/j.jaci.2003.10.011.
    1. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol. 2002;110:603–606. doi: 10.1067/mai.2002.128486.
    1. Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers J-WJ. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J. 2004;23:559–564. doi: 10.1183/09031936.04.00043504.
    1. Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, Scott C, Ho SY, House K, Dorinsky P. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma. 2004;41:797–806. doi: 10.1081/JAS-200038368.
    1. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J. 1999;13:988–992. doi: 10.1034/j.1399-3003.1999.13e10.x.
    1. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123:659–664.
    1. Marks GB, Dunn SM, Woolcock AJ. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J Clin Epidemiol. 1993;46:1103–1111. doi: 10.1016/0895-4356(93)90109-E.
    1. Wei L, Lin D, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Statistical Assoc. 1989;84:1065–1073. doi: 10.2307/2290084.
    1. GINA report. Global strategy for asthma management and prevention. 2009.
    1. Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev. 2009. p. CD003534.
    1. Adams NP, Lasserson TJ, Cates CJ, Jones P. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev. 2009. p. CD002310.
    1. Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration. 2005;72(Suppl 1):6–12.
    1. Edwards SJ, Gruffydd-Jones K, Ryan DP. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin. 2007;23:1809–1820. doi: 10.1185/030079907X210697.
    1. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103:41–49. doi: 10.1016/j.rmed.2008.09.002.
    1. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 1999;160:244–249.
    1. Bodzenta-Lukaszyk A, Pulka G, Dymek A, Bumbacea D, McIver T, Schwab B, Mansikka H. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med. 2011;105:674–682.
    1. Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, O'Brien CD. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin. 2009;25:1563–1571. doi: 10.1185/03007990902914403.
    1. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37–45. doi: 10.1186/1745-6215-10-37.
    1. Hauber AB, Mohamed AF, Johnson FR, Meddis D, Wagner S, O'Dowd L. Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications. Allergy Asthma Proc. 2009;30:139–147. doi: 10.2500/aap.2009.30.3205.
    1. Karanicolas PJ, Montori VM, Devereaux PJ, Schunemann H, Guyatt GH. A new 'mechanistic-practical' framework for designing and interpreting randomized trials. J Clin Epidemiol. 2009;62:479–484. doi: 10.1016/j.jclinepi.2008.02.009.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel